Griscelli syndrome type 2 (GS2) is an autosomal recessive hereditary disorder that combines partial hypopigmentation with severe immunodeficiency. It is caused by biallelic variants in the RAB27A gene, which alter the vesicular trafficking necessary for pigment distribution and for immune cells to eliminate infected or activated cells.
Griscelli syndrome type 2
The RAB27A gene encodes the Rab27a protein, a small GTPase involved in the transport, docking, and secretion of intracellular vesicles. This protein participates in specialized processes of different cell types, particularly in melanocytes and cytotoxic immune cells. In melanocytes, Rab27a facilitates the transport of melanosomes to the cell periphery so that pigment can be correctly transferred to the skin and hair. When Rab27a does not function properly, melanosomes aggregate abnormally, leading to characteristic hypopigmentation with silvery or light gray hair. In cytotoxic T lymphocytes and natural killer cells, Rab27a allows the release of cytotoxic granules. Its deficiency reduces the ability to destroy infected cells and favors episodes of excessive immune activation, known as hemophagocytic lymphohistiocytosis (HLH). Inheritance is autosomal recessive, and the disease is ultrarare, although clusters have been described in populations with higher consanguinity or founder effects, such as families from the Maghreb, Middle East, or Turkey.
Symptoms
The onset of SG2 usually occurs in childhood. The most characteristic signs are partial hypopigmentation, with silvery or grayish hair, light skin, and irregular pigment clumps in the hair shaft, along with a marked predisposition to develop HLH/LHH. This hyperinflammatory phase can occur with persistent fever, hepatosplenomegaly, cytopenias, liver dysfunction, and neurological symptoms such as irritability, seizures, or deterioration of the general state. Without treatment, HLH/LHH can be life-threatening.
Disease management
Management requires early diagnosis and urgent control of HLH/LHH episodes through immunosuppression, chemotherapy, and supportive treatment. Hematopoietic stem cell transplantation (HSCT) is the only treatment with curative potential for the immunological defect and is recommended before irreversible neurological damage occurs. Partial albinism is managed with photoprotection, dermatological and ophthalmological follow-up, and family genetic counseling.
Genes analyzed
Bibliography
Maimaris J, Roa-Bautista A, Sohail M, et al. Griscelli Syndrome Type 2: Comprehensive Analysis of 149 New and Previously Described Patients with RAB27A Deficiency. J Clin Immunol. 2024 Nov 28;45(1):50.
Gailson T, Pandit S, Chandrasekaran S. Griscelli syndrome type 2. QJM. 2020 Feb 1;113(2):137.
Halimy B, Radi A, Laaraje A, et al. Griscelli Syndrome Type 2 Revealed by Macrophage Activation Syndrome: Two Cases From the Same Family. Cureus. 2025 Sep 25;17(9):e93180.
